BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 28476852)

  • 1. Relationship Between Circulating Tumor Cells and Annexin A2 in Early Breast Cancer Patients.
    Bystricky B; Cierna Z; Sieberova G; Janega P; Karaba M; Minarik G; Benca J; Sedlackova T; Jurisova S; Gronesova P; Pindak D; Macuch J; Mardiak J; Mego M
    Anticancer Res; 2017 May; 37(5):2727-2734. PubMed ID: 28476852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
    Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship Between Circulating Tumor Cells and Tissue Plasminogen Activator in Patients with Early Breast Cancer.
    Bystricky B; Jurisova S; Karaba M; Minarik G; Benca J; Sedlácková T; Tothova L; Vlkova B; Cierna Z; Janega P; Manasova D; Gronesova P; Pindak D; Mardiak J; Celec P; Mego M
    Anticancer Res; 2017 Apr; 37(4):1787-1791. PubMed ID: 28373442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients.
    Mego M; Karaba M; Minarik G; Benca J; Sedlácková T; Tothova L; Vlkova B; Cierna Z; Janega P; Luha J; Gronesova P; Pindak D; Fridrichova I; Celec P; Reuben JM; Cristofanilli M; Mardiak J
    Breast J; 2015; 21(2):155-60. PubMed ID: 25623304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.
    Cierna Z; Mego M; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Cingelova S; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2014 Jun; 14():472. PubMed ID: 24972610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.
    Mego M; Karaba M; Minarik G; Benca J; Silvia J; Sedlackova T; Manasova D; Kalavska K; Pindak D; Cristofanilli M; Reuben JM; Mardiak J
    Anticancer Res; 2019 Apr; 39(4):1829-1837. PubMed ID: 30952723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
    Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
    BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer.
    Long Y; Chong T; Lyu X; Chen L; Luo X; Faleti OD; Deng S; Wang F; He M; Qian Z; Zhao H; Zhou W; Guo X; Chen C; Li X
    J Exp Clin Cancer Res; 2022 Oct; 41(1):301. PubMed ID: 36229838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxa2 binds to STAT3 and promotes epithelial to mesenchymal transition in breast cancer cells.
    Wang T; Yuan J; Zhang J; Tian R; Ji W; Zhou Y; Yang Y; Song W; Zhang F; Niu R
    Oncotarget; 2015 Oct; 6(31):30975-92. PubMed ID: 26307676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients.
    Todenhöfer T; Hennenlotter J; Dorner N; Kühs U; Aufderklamm S; Rausch S; Bier S; Mischinger J; Schellbach D; Hauch S; Feniuk N; Bedke J; Gakis G; Stenzl A; Schwentner C
    J Cancer Res Clin Oncol; 2016 May; 142(5):1013-20. PubMed ID: 26910601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
    Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
    Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer.
    Mego M; Cholujova D; Minarik G; Sedlackova T; Gronesova P; Karaba M; Benca J; Cingelova S; Cierna Z; Manasova D; Pindak D; Sufliarsky J; Cristofanilli M; Reuben JM; Mardiak J
    BMC Cancer; 2016 Feb; 16():127. PubMed ID: 26896000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
    Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
    Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.
    Bredemeier M; Kasimir-Bauer S; Kolberg HC; Herold T; Synoracki S; Hauch S; Edimiris P; Bankfalvi A; Tewes M; Kimmig R; Aktas B
    Mol Med Rep; 2017 May; 15(5):2957-2968. PubMed ID: 28358430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer.
    Griner NB; Young D; Chaudhary P; Mohamed AA; Huang W; Chen Y; Sreenath T; Dobi A; Petrovics G; Vishwanatha JK; Sesterhenn IA; Srivastava S; Tan SH
    Mol Cancer Res; 2015 Feb; 13(2):368-79. PubMed ID: 25344575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
    Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
    Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay.
    Wang HY; Ahn S; Kim S; Park S; Jung D; Park S; Han H; Sohn J; Kim S; Lee H
    Int J Clin Oncol; 2015 Oct; 20(5):878-90. PubMed ID: 25708591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.